Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

327 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Racial disparities in outcomes of patients with stage I-III triple-negative breast cancer after adjuvant chemotherapy: a post-hoc analysis of the E5103 randomized trial.
Leonard S, Jones AN, Newman L, Chavez-MacGregor M, Freedman RA, Mayer EL, Mittendorf EA, King TA, Kantor O. Leonard S, et al. Among authors: mittendorf ea. Breast Cancer Res Treat. 2024 Apr 23. doi: 10.1007/s10549-024-07308-8. Online ahead of print. Breast Cancer Res Treat. 2024. PMID: 38649618
Clinicopathological characteristics and eligibility for adjuvant olaparib of germline BRCA1/2 mutation carriers with HER2-negative early breast cancer.
Morganti S, Jin Q, Vincuilla J, Buehler R, Ryan S, Stokes S, Parker T, Mittendorf EA, King TA, Weiss A, Partridge AH, Bychkovsky BL, Curigliano G, Tayob N, Lin NU, Garber JE, Tolaney SM, Lynce F. Morganti S, et al. Among authors: mittendorf ea. NPJ Breast Cancer. 2024 Apr 16;10(1):28. doi: 10.1038/s41523-024-00632-8. NPJ Breast Cancer. 2024. PMID: 38627457 Free PMC article.
Comprehensive Analysis Identifies Variability in PI3K Pathway Alterations in Triple-Negative Breast Cancer Subtypes.
Basho RK, Zhao L, White JB, Huo L, Bassett RL, Mittendorf EA, Thompson A, Litton JK, Ueno N, Arun B, Lim B, Valero V, Tripathy D, Zhang J, Adrada BE, Santiago L, Ravenberg E, Seth S, Yam C, Moulder SL, Damodaran S. Basho RK, et al. Among authors: mittendorf ea. JCO Precis Oncol. 2024 Mar;8:e2300124. doi: 10.1200/PO.23.00124. JCO Precis Oncol. 2024. PMID: 38484209
Evolution of HER2 expression between pre-treatment biopsy and residual disease after neoadjuvant therapy for breast cancer.
Tarantino P, Ajari O, Graham N, Vincuilla J, Parker T, Hughes ME, Tayob N, Garrido-Castro AC, Morganti S, King TA, Mittendorf EA, Curigliano G, Lin NU, Tolaney SM. Tarantino P, et al. Among authors: mittendorf ea. Eur J Cancer. 2024 Apr;201:113920. doi: 10.1016/j.ejca.2024.113920. Epub 2024 Feb 10. Eur J Cancer. 2024. PMID: 38368741 Review.
Estrogen Receptor Mutations as Novel Targets for Immunotherapy in Metastatic Estrogen Receptor-positive Breast Cancer.
Goldberg J, Qiao N, Guerriero JL, Gross B, Meneksedag Y, Lu YF, Philips AV, Rahman T, Meric-Bernstam F, Roszik J, Chen K, Jeselsohn R, Tolaney SM, Peoples GE, Alatrash G, Mittendorf EA. Goldberg J, et al. Among authors: mittendorf ea. Cancer Res Commun. 2024 Feb 22;4(2):496-504. doi: 10.1158/2767-9764.CRC-23-0244. Cancer Res Commun. 2024. PMID: 38335301 Free PMC article.
TBCRC 039: a phase II study of preoperative ruxolitinib with or without paclitaxel for triple-negative inflammatory breast cancer.
Lynce F, Stevens LE, Li Z, Brock JE, Gulvady A, Huang Y, Nakhlis F, Patel A, Force JM, Haddad TC, Ueno N, Stearns V, Wolff AC, Clark AS, Bellon JR, Richardson ET, Balko JM, Krop IE, Winer EP, Lange P, Hwang ES, King TA, Tolaney SM, Thompson A, Gupta GP, Mittendorf EA, Regan MM, Overmoyer B, Polyak K. Lynce F, et al. Among authors: mittendorf ea. Breast Cancer Res. 2024 Jan 31;26(1):20. doi: 10.1186/s13058-024-01774-0. Breast Cancer Res. 2024. PMID: 38297352 Free PMC article. Clinical Trial.
327 results